HRM/HRTP

Program: MBA and BBA

Project Final Report: Sanofi Aventis Pharmaceutical Company

Group#03 Members:

Uzair Ahmed(14172) à Introduction

Syed Usaid Bukhari(12689) à Profile of Organization
Naseer Ali(11287) à Data Collection
Anus Ahmed Khan (13286) à Finding, Conclusion, Suggestion and Limitation

Submitted to Instructor: Dr Khizer Hayat Khan

Date: 09th Sep 2022
Project Marks: ______ Marks

Campus: IQRA University (Airport Campus)

1|Page
Contents
Preface.........................................................................................................................................................3
ACKNOWLEDGEMENT.................................................................................................................................3
1) INTRODUCTION...................................................................................................................................4
2) PROFILE OF ORGANIZATION................................................................................................................4
2.1 Group History....................................................................................................................................5
2.2 Therapeutic Areas and Products:.......................................................................................................6
2.3 Vision Statement:..............................................................................................................................7
2.4 Mission Statement:............................................................................................................................8
2.5 Objective and goal.............................................................................................................................8
2.6 Our Purpose.......................................................................................................................................8
2.7 Our Core Values.................................................................................................................................8
2.8 Problem area identified.....................................................................................................................9
2.9 Benchmark.........................................................................................................................................9
3) DATA COLLECTION...............................................................................................................................9
3.1 Objective of study..............................................................................................................................9
3.2 The means of obtaining information...............................................................................................10
3.3 Execution of the project/ Analysis against benchmark....................................................................10
4) FINDINGS, CONCLUSIONS & SUGGESTIONS / RECOMMENDATIONS / LIMITATIONS........................11
4.1 Findings............................................................................................................................................11
4.2 Conclusion.......................................................................................................................................12
4.3 Recommendations/Suggestions......................................................................................................12
4.4 Limitations.......................................................................................................................................13

2|Page
Preface

This is the final report of our project in our course HRTP and HRM, which is a prerequisite of
our course instructor Dr Khizer Hayat Khan. The aim of this report is to apply the concepts
learned in this course. We worked on company "SANOFI Pakistan " in our project.

ACKNOWLEDGEMENT
In the name of Allah, The Most Gracious and The Most Merciful. We would like to thank
Almighty ALLAH for giving us the ability and strength to complete our future studies project. It
was guidance that we were able to take this report as a challenge and in the end; He bestowed us
with his blessings.

A work is never a work of an individual. A special note of thanks to our honorable Teacher, who
is the lecturer of Iqra University, for providing his valuable guidance, comments, ideas and
suggestions throughout the course and without her support and guidance this project would not
have been accomplished.

A special thanks for our team members, who have whole heartedly worked to bring the best out
of this project. We all have learned and earned valuable experience during this course.

3|Page
1) INTRODUCTION

The firm that is now known as Sanofi Pakistan has been operating in Pakistan for 55 years, using
efficient, high-quality products to save millions of lives and enhance the quality of life of many
more. SANOFI is a pioneering provider of healthcare services with a focus on patient
requirements. A broad selection of pharmaceuticals, consumer healthcare items, generic drugs,
and animal health products. A pioneer in human vaccination.
Very extensive and well-rounded position in both established and emerging markets. More than
110,000 workers across 100 nations, with a net worth of €33 billion in 2013 and €37.76 billion in
net revenue in 2021.

2) PROFILE OF ORGANIZATION
SANOFI, a global and diversified healthcare leader discovers, develops and distributes
therapeutic solutions focused on patients needs. Sanofi has care strengths in healthcare, with 11
growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare,

4|Page
and emerging markets, Cardiology, Vaccine and Nephrology. Through the acquisition of
Genzyme, Sanofi has strongly reinforced its footprint in rare diseases.

2.1 Group History

Since the firm that is now known as Sanofi Pakistan first arrived in Pakistan more than 50 years
ago, millions of lives have been saved and countless others' quality of life has been enhanced
because to its efficient, high-quality products.
On December 8, 1967, the business was established as Hoechst Pakistan Limited. In 1972,
production of pharmaceuticals and specialty chemicals began. The business went public and
listed on the Pakistan Stock Exchange in 1977. In 1985, agrochemical formulation began.
The Specialty Chemicals business was sold to Clariant Pakistan Limited the following year,
while the Agriculture business was spun off into a new legal organization called AgrEvo
Pakistan (Private) Limited in 1996. In June 1996, Hoechst Pakistan Limited changed its name to
Hoechst Marion Roussel (Pakistan) Limited, and from that point forward, only pharmaceutical-
related activities remained its primary activity.
Globally, Hoechst AG and Rhone Poulenc S.A. integrated their life sciences businesses in
December 1999 to form Aventis S.A. In November 2000, the business in Pakistan changed its
name to Aventis Pharma (Pakistan) Limited.
Aventis Pharma (Pakistan) Limited and Rhone Poulenc Rorer Pakistan (Private) Limited
amalgamated locally in accordance with the global merger, and the business began operating as
Aventis Limited in April 2003.
Aventis S.A. was purchased by Sanofi Synthelabo in 2004 to create Sanofi-Aventis S.A. Sanofi-
Aventis Pakistan Ltd became the official name of the corporation in September 2005 as a result.
Sanofi-Aventis changed their name to Sanofi in 2011. However, Sanofi-Aventis Pakistan
Limited remains the company's legal name.
On December 20, 2021, Packages Limited made a public announcement announcing that its
Board of Directors had approved it in principle to join an investor consortium to assess the
possibility of the consortium purchasing all of the 52.87% of the company's shares held by
parent company Sanofi Foreign Participations B.V. The Consortium is headed by Packages
Limited and consists of the Arshad Ali Gohar Group's affiliates as well as IGI Investments. In

5|Page
return, the Parent Company gave the Consortium permission to investigate the Company in-
depth. However, no major development has been made up to the finalization of this annual
report.
There are no guarantees those discussions between Sanofi and the Consortium will result in a
legally binding agreement or that the transaction will take place at all at this time.
Sanofi introduced a new worldwide brand identity and logo in February 2022. The slogan "We
chase the miracles of science to better people's lives" was introduced in place of the previous
slogan "Empowering Life"

2.2 Therapeutic Areas and Products:

Company covers major therapeutic areas

1) Diabetes

In Diabetes, Sanofi offers Amaryl, Amaryl MSR, Daonil and Neodipar in oral anti Diabetics
solution. And in Insulin’s Sanofi has products of Lantus, Toujeo, Apidra and Soliqua

6|Page
2) Oncology

In Oncology, Sanofi offers 4 products namely Jevtana, Taxotere, Eloxatin and Fludara.

3) Pain management

In Pain management, Sanofi has 4 products Nospa, Muscoril, Profenid and Stemetil.

4) Allergy management

In Allergy management, Sanofi has 6 medicines Telefast, Telefast D, Avil, Tixylix, Nasacort AQ
and Phenergan.

5) Antibiotics

In Antibiotics, Sanofi has Claforan, Orelox, Targocid Tarivid, Tavanic and Aventriax.

6) Diarrhea

In Diarrhea, Sanofi has Flagyl, Flagyl Plus and Enterogermina

7) Cardiology

In Cardiology, Sanofi has Plavix, Approvel, Co-approvel, Tritace, Co-tritace, Winstor, Lasix and
Lasoride, and Clexane.

8) Emergency Care

In Emergency Care, Sanofi has 1 product namely Heamaccel

9) Vaccine

In Sanofi Pasteur they have products IPOL vaccine, Menquadfi, Pentacel, Quadracel, Tenivac,
Tubersol, Typhim VI, Imovax Rabies, ActHIB, Adacel, Daptacel, and Imogam

10) Consumer Healthcare

In Consumer Healthcare, Sanofi has a product namely Selsun blue.

11) Nephrology

In Nephrology, Sanofi has a product namely Renvela

2.3 Vision Statement:

7|Page
Their Vision statement is “To enhance the quality of life of the greatest number through
providing a continuum of care by answering unmet medical needs of the community and
promoting access to quality healthcare”

2.4 Mission Statement:

Their Mission is that they want to safeguard, empower, and support persons with health issues so
they can enjoy their lives to the fullest.

2.5 Objective and goal

Sanofi is devoted to enhancing how they conduct their business operations while helping to
address global challenges and generating sustainable shared value, according to the association's
mission statement.

2.6 Our Purpose

Our Objective is to make people's lives better, we pursue scientific miracles.

2.7 Our Core Values

Our principles eventually determine our company's DNA by defining our actions, ethics, and
sense of ethics.

Teamwork

Putting out our best effort to enhance people's lives and succeed as One Sanofi.

Integrity

Operate with integrity and openness to uphold the highest moral and professional standards.

Respect

Accepting the diversity, various viewpoints, and needs of our employees, clients, and
communities.

Courage

8|Page
Take risks, be bold in your innovation, and learn from your mistakes.

2.8 Problem area identified

Sanofi S.A. is a French multinational pharmaceutical and healthcare public limited company
headquartered in Paris, France.  Sanofi Aventis was basically a pharmaceutical and healthcare
company which was failed in Pakistan and sold all its shares in December 2021. Sanofi was
failed in Pakistan due to following reasons mentioned below
1. Because of governmental policies and dollar rates increases and profit margin reduces.
2. No gold standard product launch over a period of time.
3. Sanofi global policies not fit and beneficial in Pakistani market.
4. Conflict with French government due to Protection of the Messenger’s holiness and the
protection of the inviolability of Din Blame game from Ribald advertisements in France. And
in anger, Consumers boycotted and limited the use of French products and company suffered
losses in Pakistan.

2.9 Benchmark
1. Solid competitors like Novo nordisk and Eli Lilly in MNCs.
2. Launch a gold standard product that is committed to high quality and fit the need of
customer.
3. Set company policy that best fit in Pakistani market.
4. Improve the economic performance and to be in Top ranked Position within 5 years.
5. Meeting Objectives in 2022 and beyond.

3) DATA COLLECTION

3.1 Objective of study

1. Why Sanofi Aventis shut its plant in Pakistan?

2. Why Sanofi Aventis economic parameter not meets the benchmark target?

9|Page
3. Why Sanofi Aventis business was shrinking?

4. Why Sanofi Aventis unable to meet previous targeted objectives?

5. Why Sanofi Aventis cannot use attractive advertising strategies, to advertise well through the
social media, newspapers, billboards, websites and other sources its product?

6. Why prices of its product are high as compare to its competitor price?

7. Why Sanofi Aventis unable to achieve a strong market position and gain a large market
share?

8. Why Sanofi Aventis unable to meet demand and supply of its product in Pakistan?

3.2 The means of obtaining information

1. Data was collected was collected from direct interviews and focus group and collected the
feed back

2. Through physical questionnaire survey and gathered feedback

3. By observation and observing people interact with the company and products and can
witness it in real time.

3.3 Execution of the project/ Analysis against benchmark

Showcasing procedures are dynamic. Every age accompanies new requests, necessities, and
inclinations. Likewise, data and correspondence advancements set in. Such factors upset the
marketing, promoting, and commercial procedures that different business elements use.

1. Sanofi Pakistan stays ranked in top 10 MNCs with close rivalry with Novo Nordisk and Eli
lilly in Diabetes. To stand worldwide contest for the powerful buyer needs, Sanofi Pakistan
utilizes dynamic, imaginative, and innovative advertising procedures that target specificities
of purchasers.
2. Launch a gold standard product that is committed to high quality and fit the need of
customer. Sanofi need to launch more gold standard products to maintain its position in
market and increase its profit like its previous gold standard products Amaryl, Lantus and
flagyl etc.

10 | P a g e
3. Sanofi international having many limitations as compare to local companies because their
policies are generalized and applied globally. But when it becomes to Sanofi Pakistan it
reform its policies towards its staff and as well as customers to achieve its goals.
4. Sanofi is performing well economically because localization remove its currency exchange
factor.(France)
5. Policy making after localization shows that company is performing well and predicted it will
achieve its coming goals also.

We accept that this examination will assist us with being familiar with the Sanofi Pakistan
Company and how they are going to accomplish their target.

4) FINDINGS, CONCLUSIONS & SUGGESTIONS / RECOMMENDATIONS /

LIMITATIONS

4.1 Findings
1. Sanofi Pakistan company close their operation in Pakistan in 2021 due to heavy increase in
taxes on importing, packaging and raw material also and operating in losses.

2. Sanofi Pakistan Pharma Company did not meet the benchmark targets because of
uncertainty, increasing cost on fuel, electricity, labor wages and raw material these factors
increase the basic cost of product but due to DRAP restrictions in price and company profit
reduced so the supply is decreasing.

3. Due to shrink in revenue. In addition in cost of production almost 70 percent of revenue due
to currency devaluation. Dollar exchange rate in May 2021 was around 150 and now in Sep
2022 it is 218.

4. Because of local companies are capturing the market quickly due to low cost profit margin
and goal reaching budget is not sufficient.

5. Sanofi global policies do not allow advertising well through the social media like twitter,
instagram, YouTube, newspapers, billboards, websites and other sources its product and it is
costly also.

11 | P a g e
6. Because of research and international quality standards are maintained and products directly
imported from 1st world country, the cost of production is higher than the local companies.

7. Because Sanofi has high and strong ethics in pharmaceutical industry, they cannot ruin its
name to get some extra business for some personal works of client. But other companies are
facilitating and fulfilling all the needs, wants and demands of customer and making their
customer happy that’s why unable to get delta growth positive in yearend 2021.

8. Sanofi Aventis unable to meet demand and supply of its product in Pakistan due to supply
chain problem. This problem has witnessed an unprecedented disruption all around the world
after COVID-19.  In fact, this represents one the major challenges facing by the
pharmaceutical industry in this decade.

4.2 Conclusion
We as a whole realize that some MNCs like Novo Nordisk and Eli Lilly and all the national
companies know the basic need of their customer and react accordingly and they are getting
benefit and attaining the good share but Sanofi fails in Pakistan due to restrict on same policy
and procedures and did not change accordingly so meet the dust. It is also fail due to poor
attention given towards the ad campaign. Modern products shrink its business significantly.
Another reason is uncertainty in market and dollar rate is climbing high and cannot change the
price of product. Because Sanofi global did not change its policy as per demands of Pakistani
market they fail to perform better.

But After 2021 Sanofi Pakistan is inclining again and delta positive growth observed due to the
change adopted after National setup and gained the popularity again.

4.3 Recommendations/Suggestions
1. Sanofi Pakistan bunch the executives involves the objective methodology for their item's
advancement, which is essentially underlining the item credits in the advertisements rather than
enthusiastic methodology. Thus, to be more successful in the advertisement crusade they should
involve passionate methodology in their promotions to draw in more clients.

2. Lower the cost of product

12 | P a g e
3. Reduce paper and operation workflows

4.4 Limitations
1. The biggest challenge faced by the Sanofi is the complete freezing of prices of its
pharmaceutical products. 
2. The other issue is delays in approval of new molecules, which can often take several years,
depriving patients of the benefits of the latest remedy.
3. Unethical marketing
4. Affordability of medicine
5. Supply chain disruption

…………………………………………………………………………………

13 | P a g e